SCHEMBL24137480

SCHEMBL24137480

Nc1nc2ccc(-c3cncc(NCc4ccccc4)c3)cc2[nH]1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT1 P31749 1/20 0.47
▸ EGFR P00533 1/20 0.44
▸ PIK3CA P42336 1/20 0.44
▸ RAB9A P51151 4/20 0.44
▸ SMN1; SMN2 Q16637 4/20 0.44
▸ HTT P42858 2/20 0.44
▸ LMNA P02545 2/20 0.44
▸ HIF1A Q16665 2/20 0.44
▸ GFER P55789 1/20 0.44
▸ KDR P35968 1/20 0.43
▸ KCNH2 Q12809 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ DHFR P00374 2/20 0.42
▸ TP53 P04637 2/20 0.41
▸ CYP11B2 P19099 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24137465 0.82 RAB9A (0.46) PIK3CARAB9ASMN1; SMN2HTTLMNA
SCHEMBL24137786 0.79 JAK2 (0.57) AKT1KCNH2DHFR
SCHEMBL22191227 0.79 PDE3B (0.47) EGFRPIK3CAKDRKCNH2KDM4E
SCHEMBL24137530 0.78 FGFR1 (0.56) AKT1KDRKCNH2MAPK1CLK4
SCHEMBL24137560 0.77 CDK2 (0.57) AKT1KDRMAPK1CLK4
SCHEMBL13743125 0.76 KCNH2 (0.56) EGFRPIK3CAHTTKDRKCNH2
SCHEMBL24137549 0.75 FYN (0.61) AKT1EGFRPIK3CAKDRKCNH2
SCHEMBL24137563 0.75 CCNC (0.61) AKT1KDRMAPK1CLK4MAPK14
SCHEMBL24137564 0.75 PKM (0.49) AKT1EGFRPIK3CAKDRKCNH2
SCHEMBL30596234 0.75 PKM (0.49) AKT1EGFRPIK3CAKDRKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI 2023-07-27 — — US disclosed
WO-2021263129-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2021-12-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234935-A1 KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE PACSIN2, MAP3K20, PHKG1 AKT1 108/4885EGFR 800/4885PIK3CA 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback